Cybin Inc. (CYBN) Financial Analysis & Valuation | Quarter Chart
Cybin Inc. (CYBN)
CYBNPrice: $8.28
Fair Value: 🔒
🔒score
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety dis... more
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The c... more
Description
Shares
| Market Cap | $413.02M | Exchange | AMEX |
| Sector | Healthcare | Industry | Biotechnology |
| Country | CA | CEO | Eric So |
| IPO Date | 2019-09-13 | CAGR | — |
| Employees | 50 | Website | www.cybin.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
CYBN chart loading...
Fundamentals
Technicals
| Enterprise Value | $453.63M | P/E Ratio | -2.2 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 6416006262.9 |
| P/CF Ratio | -19050736570.33 | P/FCF Ratio | -22344406851.63 |
| EPS | $-3.77 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | — | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -0.32% | ROA | -0.33% |
| ROCE | -0.46% | Current Ratio | 12.6 |
| Quick Ratio | 12.6 | Cash Ratio | 10.24 |
| Debt/Equity | — | Interest Coverage | — |
| Altman Z Score | 1.16 | Piotroski Score | 2 |